Fredun Pharmaceuticals Hits New 52-Week High of Rs.1971.25 Marking Significant Milestone

On 18 Nov 2025, Fredun Pharmaceuticals recorded an intraday peak of Rs.1971.25, marking its highest price in the past year and an all-time high for the company. The stock opened with a gap up of 4.93% and closed the day with a gain of 4.40%, outperforming its sector by 5.29%. This marks the third consecutive day of gains, during which the stock has delivered a cumulative return of 15.57%.

Fredun Pharmaceuticals is currently trading above all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling sustained upward momentum. This technical positioning supports the stock’s recent rally and highlights investor confidence in its underlying fundamentals.

Over the past year, Fredun Pharmaceuticals has delivered a remarkable return of 182.89%, significantly outpacing the Sensex’s 9.45% performance during the same period. The stock’s 52-week low was Rs.635, highlighting the scale of its upward trajectory. This performance is notable within the Pharmaceuticals & Biotechnology sector, where Fredun has demonstrated consistent growth metrics.

Financially, the company’s net sales have shown an annual growth rate of 39.73%, while operating profit has expanded at a rate of 55.03%. The net profit growth stands at 127.87%, with the company reporting positive results for six consecutive quarters, including the latest quarter ending September 2025. Operating profit to interest ratio for the quarter is at 2.89 times, and profit before tax excluding other income reached Rs.13.01 crores, growing at 71.64%. Net sales for the quarter were Rs.145.30 crores, reflecting a growth of 35.35%.

Fredun Pharmaceuticals’ return on capital employed (ROCE) is recorded at 20.2%, accompanied by an enterprise value to capital employed ratio of 3.3, indicating an attractive valuation relative to its peers. The company’s PEG ratio stands at 0.5, suggesting a valuation that is reasonable in the context of its earnings growth.

In comparison, the Sensex opened positively on the same day, rising 91.42 points initially, but later declined by 393.30 points to close at 84,649.07, down 0.36%. The Sensex remains 0.76% below its own 52-week high of 85,290.06 and is trading above its 50-day moving average, which itself is positioned above the 200-day moving average, indicating a broadly bullish market trend.

Fredun Pharmaceuticals’ market capitalisation grade is 4, reflecting its standing within the Pharmaceuticals & Biotechnology sector. The company’s mojo score is 77.0, with a mojo grade adjustment recorded on 29 Jul 2025, reflecting a revision in its evaluation from Hold to Buy. This adjustment coincides with the stock’s recent price momentum and financial performance.

Despite the company’s size and market presence, domestic mutual funds currently hold no stake in Fredun Pharmaceuticals. This absence of mutual fund participation may reflect a cautious stance or valuation considerations within institutional circles, though it does not detract from the company’s demonstrated financial metrics and market performance.

Fredun Pharmaceuticals’ consistent quarterly results and strong financial ratios underpin the stock’s recent rally to its 52-week high. The company’s ability to sustain growth in net sales, operating profit, and net profit over multiple quarters has contributed to its upward price movement and technical strength.

As the stock continues to trade above key moving averages and outperforms its sector, the milestone of Rs.1971.25 as a 52-week high marks a significant achievement for Fredun Pharmaceuticals in the current market cycle.

Get 2 full years of MojoOne Premium for only Rs. 12,999. Subscribe for 1 year and we'll add another year FREE. Offer valid for a limited time. Start Saving Now →